Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
Year: 2022
Type: article
Abstract: Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies.The virtual Immunotherapy Bridge (December 1st-2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.
Authors: Paolo A. Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Luigi Buonaguro, Sandra Demaria, Leisha A. Emens, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Christopher A. Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M. Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M. Taube, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Azienda Ospedaliera S.Maria, Weill Cornell Medicine, Magee-Womens Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Inserm, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Laboratoire d’immunologie intégrative du cancer, Georgetown University, Memorial Sloan Kettering Cancer Center, Lonza (United States), Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Winship Cancer Institute, University of Pennsylvania, Herlev Hospital, Copenhagen University Hospital, Johns Hopkins University, Providence Portland Medical Center, Moffitt Cancer Center, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W4281677392